Article
Medicine, General & Internal
Prasanna Venkataraman, Amanda L. Neil, Geoffrey K. Mitchell, Tony Stanton, Stephen Nicholls, Andrew M. Tonkin, Gerald F. Watts, Thomas H. Marwick
Summary: This study compared the cost-effectiveness of coronary artery calcium (CAC) score-guided statin therapy criteria and American College of Cardiology/American Heart Association (ACC/AHA) guidelines with selection according to Australian guidelines. The findings showed that CAC score-guided selection was cost-effective for people with 5-year ACVDR of at least 5%.
MEDICAL JOURNAL OF AUSTRALIA
(2023)
Review
Multidisciplinary Sciences
Akhil Sasidharan, Bhavani Shankara Bagepally, S. Sajith Kumar, Kayala Venkata Jagadeesh, Meenakumari Natarajan
Summary: The study found that Ezetimibe plus statin therapy is cost-effective compared to other lipid-lowering therapeutic agents or placebo in high-income countries and for primary prevention, but there is limited evidence from lower-middle-income countries and the societal perspective.
Article
Cardiac & Cardiovascular Systems
Prasanna Venkataraman, Hiroshi Kawakami, Quan Huynh, Geoffrey Mitchell, Stephen J. Nicholls, Tony Stanton, Andrew Tonkin, Gerald F. Watts, Thomas H. Marwick
Summary: The study found that using the CAC strategy to guide statin treatment in individuals with a family history of premature coronary artery disease was more cost-effective than traditional risk factor-based prediction alone. The cost-effectiveness was driven by CAC acquisition and statin prescription cost, and improved with certain patient subgroups, such as males over 60 years of age with a 10-year risk over $7.5%.
JACC-CARDIOVASCULAR IMAGING
(2021)
Article
Cardiac & Cardiovascular Systems
Derek S. Chew, Patricia A. Cowper, Hussein Al-Khalidi, Kevin J. Anstrom, Melanie R. Daniels, Linda Davidson-Ray, Yanhong Li, Robert E. Michler, Julio A. Panza, Ileana L. Pina, Jean L. Rouleau, Eric J. Velazquez, Daniel B. Mark
Summary: The STICH trial showed that coronary artery bypass grafting (CABG) is economically favorable compared to medical therapy (MED) in patients with ischemic cardiomyopathy and reduced left ventricular function.
Article
Surgery
Domenico R. Nastasi, Joseph Moxon, Richard Norman, Alexandra F. Trollope, Sophie Rowbotham, Frank Quigley, Jason Jenkins, Jonathan Golledge
Summary: The study estimated the benefit and cost-effectiveness of administering PCSK9 inhibitors to patients with peripheral artery disease. The findings suggest that intensive lowering of LDL-C can significantly reduce the risk of MACE and MALE, especially in patients with CLTI.
JOURNAL OF VASCULAR SURGERY
(2021)
Article
Cardiac & Cardiovascular Systems
Ciaran N. Kohli-Lynch, Brandon K. Bellows, Yiyi Zhang, Bonnie Spring, Dhruv S. Kazi, Mark J. Pletcher, Eric Vittinghoff, Norrina B. Allen, Andrew E. Moran
Summary: The study revealed that around 27% of ASCVD-free young adults in the United States have LDL-C levels >_130 mg/dL, and 9% have LDL-C >_160 mg/dL. Using statins or lifestyle interventions for lipid-lowering can prevent ASCVD events and increase QALYs compared to standard care.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Yuanming Xing, Yulan Qiu, Luting Yang, Zuyi Yuan, Yan Wang
Summary: This study aimed to assess the cost-effectiveness of PAD screening using ABI test and subsequent low-dose rivaroxaban administration in Chinese CAD patients. The study found that ABI screening resulted in an incremental cost of RMB4,959 and an incremental QALY of 0.054 over a 25-year period, with an ICER of RMB91,936 per QALY gained. However, cost-effective screening could be achieved by reducing the cost of rivaroxaban or using domestic-brand rivaroxaban.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2023)
Article
Medicine, General & Internal
Victoria McCreanor, Alexandra Nowbar, Christopher Rajkumar, Adrian G. Barnett, Darrel Francis, Nicholas Graves, William E. Boden, William S. Weintraub, Rasha Al-Lamee, William A. Parsonage
Summary: The cost-effectiveness of percutaneous coronary intervention (PCI) compared with placebo in patients with single-vessel coronary artery disease and angina on anti-anginal medication exceeds the threshold used by the National Institute of Health and Care Excellence. The estimated Incremental cost-effectiveness ratio (ICER) for PCI is £90,218/QALY gained, and the results were robust under sensitivity analyses.
Article
Geriatrics & Gerontology
Mervi Rantsi, Kaisu H. Pitkala, Hannu Kautiainen, Virva Hyttinen, Eila Kankaanpaa
Summary: This study analyzed the economic impact of an educational intervention on potentially inappropriate medication use in older people. The results showed that the educational intervention was less costly but less effective in terms of quality-adjusted life years compared to usual treatment. However, there were uncertainties in the results.
Article
Pharmacology & Pharmacy
Agata Gorniak, Adrianna Zlocinska, Mateusz Trojan, Adrianna Pecak, Bozena Karolewicz
Summary: The simvastatin-ezetimibe solid dispersion prepared using the co-grinding method showed improved dissolution of ezetimibe regardless of simvastatin content. The study also confirmed a simple eutectic phase equilibrium diagram between simvastatin and ezetimibe.
Article
Health Care Sciences & Services
Sameera Senanayake, Ureni Halahakone, Bridget Abell, Sanjeewa Kularatna, Victoria McCreanor, Steven M. McPhail, Julie Redfern, Tom Briffa, William Parsonage
Summary: Traditional cardiac rehabilitation is effective but underutilized. This study assessed the cost-effectiveness of a hybrid cardiac telerehabilitation program in Australia and found that it is unlikely to be economically viable compared to current practice.
BMC HEALTH SERVICES RESEARCH
(2023)
Article
Cardiac & Cardiovascular Systems
Jie Gao, Jun Lu, Wenjun Sha, Bilin Xu, Cuiping Zhang, Hongping Wang, Juan Xia, Hong Zhang, Wenjun Tang, Tao Lei
Summary: This study evaluated the association between the neutrophil to HDL-C ratio (NHR) and the degree of coronary stenosis in patients with stable coronary artery disease (CAD). The results showed that NHR was not only associated with the occurrence and seriousness of CAD, but also a better predictor of severe CAD than neutrophil, HDL-C or LDL-C/HDL-C.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Psychiatry
Samira Barbara Jabakhanji, Jan Sorensen, Robert M. Carney, Chris Dickens, Martin Dempster, Jonathan Gallagher, Isabela Caramlau, Frank Doyle
Summary: This study assessed the cost-effectiveness of four interventions for depression in individuals with coronary artery disease and found that group exercise was the most cost-effective intervention after 8 weeks.
JOURNAL OF PSYCHOSOMATIC RESEARCH
(2022)
Article
Medicine, General & Internal
Rutger W. M. Brouwers, Esmee K. J. van der Poort, Hareld M. C. Kemps, M. Elske van den Akker-van Marle, Jos J. Kraal
Summary: This study compared the cost-effectiveness of cardiac telerehabilitation (CTR) with relapse prevention to traditional center-based cardiac rehabilitation (CR) among patients with coronary artery disease. The results suggest that CTR may be a cost-effective alternative intervention for the treatment of these patients, potentially increasing its implementation in clinical practice.
Article
Cardiac & Cardiovascular Systems
Ankur Pandya, Yuan-Jui Yu, Yin Ge, Eike Nagel, Raymond Y. Kwong, Rafidah Abu Bakar, John D. Grizzard, Alexander E. Merkler, Ntobeko Ntusi, Steffen E. Petersen, Nina Rashedi, Juerg Schwitter, Joseph B. Selvanayagam, James A. White, James Carr, Subha V. Raman, Orlando P. Simonetti, Chiara Bucciarelli-Ducci, Lilia M. Sierra-Galan, Victor A. Ferrari, Mona Bhatia, Sebastian Kelle
Summary: Based on the research, cardiovascular magnetic resonance (CMR) is usually a cost-effective option compared to relevant comparators for assessing significant coronary artery disease. The findings suggest that CMR can provide both health benefits and cost savings, making it a favorable choice for evaluating CAD.
JOURNAL OF CARDIOVASCULAR MAGNETIC RESONANCE
(2022)